Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2014 8
2015 15
2016 22
2017 29
2018 36
2019 29
2020 10
2021 6
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 30818917

145 results

Results by year

Filters applied: . Clear all
Page 1
[Efficacy and safety of paritaprevir/ritonavir/ombitasvir combined with dasabuvir in non-cirrhotic Asian adult patients with newly diagnosed and treated chronic HCV genotype 1b infection: a randomized, double-blind, placebo-controlled study - China data].
Wei L, Cheng J, Luo J, Li ZP, Duan JL, Hou JD, Jia MX, Zhang Y, Huang Q, Xie GJ, Wang DL, Yang W, Zhao CY, Zhao G, Tang SM, Lin GZ, Gong JJ, Niu ZL, Gao JF, Sarah KB, Linda F, Niloufar M, Wang Y, Wang J. Wei L, et al. Zhonghua Gan Zang Bing Za Zhi. 2018 May 20;26(5):359-364. doi: 10.3760/cma.j.issn.1007-3418.2018.05.009. Zhonghua Gan Zang Bing Za Zhi. 2018. PMID: 29996204 Clinical Trial. Chinese.
[Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir combined with ribavirin in Asian adult patients with chronic HCV genotype 1b infection and compensated cirrhosis].
Wei L, Wang GQ, Sarah J, Cheng Q, Xie MR, Wang M, Xu ZP, Duan JL, Hou MX, Zhang YX, Zhang G, Tang W, Zhao SM, Lin ZS, Jia JJ, Niu ZL, Gao H, Yuan MH, Lin XM, Zhou JD, Luo Y, Linda F, Niloufar M, Wang Y, Jia J. Wei L, et al. Zhonghua Gan Zang Bing Za Zhi. 2018 May 20;26(5):353-358. doi: 10.3760/cma.j.issn.1007-3418.2018.05.008. Zhonghua Gan Zang Bing Za Zhi. 2018. PMID: 29996203 Chinese.
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
Ferenci P, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D, Marra F, Kleine H, Dorr P, Charafeddine M, Crown E, Bondin M, Back D, Flisiak R. Ferenci P, et al. J Viral Hepat. 2019 Jun;26(6):685-696. doi: 10.1111/jvh.13080. Epub 2019 Mar 5. J Viral Hepat. 2019. PMID: 30739368 Free PMC article.
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Petta S, et al. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28497758
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
Welzel TM, Asselah T, Dumas EO, Zeuzem S, Shaw D, Hazzan R, Forns X, Pilot-Matias T, Lu W, Cohen DE, Feld JJ. Welzel TM, et al. Lancet Gastroenterol Hepatol. 2017 Jul;2(7):494-500. doi: 10.1016/S2468-1253(17)30071-7. Epub 2017 Apr 14. Lancet Gastroenterol Hepatol. 2017. PMID: 28416221 Clinical Trial.
Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, Escudero-Vilaplana V, Collado Borrell R, Ibañez-Garcia S, Lallana Sainz E, Lobato Matilla E, Lorenzo-Pinto A, Manrique-Rodriguez S, Fernandez-Llamazares CM, Marzal-Alfaro M, Ribed A, Romero Jimenez RM, Sarobe Gonzalez C, Herranz A, Sanjurjo M. Chamorro-de-Vega E, et al. Ann Pharmacother. 2016 Nov;50(11):901-908. doi: 10.1177/1060028016659306. Epub 2016 Jul 20. Ann Pharmacother. 2016. PMID: 27422641
145 results